The CAR/CCR strategy additionally protects against CD19-directed on-target off-tumor side effects both in vitro and in vivo, since binding to CD19 antigen alone is not sufficient to trigger full CAR/CCR-mediated T cell activation. This evidence concerns the gene CD19 and neoplasm.